Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation

被引:30
作者
Houtenbos, I
Westers, TM
Stam, AGM
de Gruijl, TD
Scheper, RJ
Ossenkoppele, GJ
van de Loosdrecht, AA
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Haematol BR 250, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
关键词
acute myeloid leukaemia; immunotherapy; antigen presenting cells; serum-free culture;
D O I
10.1007/s00262-003-0389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose.. Immunotherapy holds promise as a new strategy for the eradication of residual cells in acute myeloid leukaemia (AML). Leukaemic antigen presenting cells (APCs) combining optimal antigen presentation and tumour antigenicity could be used as potent T cell activators. For clinical purposes it is desirable to culture APCs under serum-free conditions. Therefore, we compared morphological, immunophenotypical and functional outcome of the serum-free culture of AML-APCs to their serum-enriched culture. Methods.. AML blasts (n=19) were cultured in the presence of either a cytokine mix or calcium ionophore (CI) for 14 and 2 days, respectively, in FCS-containing medium (FCS), StemSpan serum-free medium (SP) and CellGro serum-free medium (CG). After culture relative yields were calculated and immunophenotypic analysis of APC markers was performed. The mixed leukocyte reaction (MLR) was used to determine T cell stimulating capacity. Results.. Serum-free culture of AML-APCs resulted in comparable morphology, relative yields and immunophenotype to serum-enriched culture. By comparing both serum-free media we observed a trend towards a more mature phenotype of CI-cultured AML-APCs in SP. MLR showed that serum-free cultured cells have equal T cell stimulatory capacity in comparison with serum-enriched culture. Conclusion.. These data show that the serum-free culture of AML-APCs is feasible and that these APCs are comparable to serum-enriched cultured AML-APCs with regard to morphological, immunophenotypical and functional characteristics. These AML-APCs are suitable for the development of active specific immunisation protocols which meet the criteria for good clinical practise (GCP).
引用
收藏
页码:455 / 462
页数:8
相关论文
共 31 条
[11]   Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents [J].
Koski, GK ;
Schwartz, GN ;
Weng, DE ;
Gress, RE ;
Engels, FHC ;
Tsokos, M ;
Czerniecki, BJ ;
Cohen, PA .
BLOOD, 1999, 94 (04) :1359-1371
[12]  
Koski GK, 2001, EUR J IMMUNOL, V31, P3773, DOI 10.1002/1521-4141(200112)31:12<3773::AID-IMMU3773>3.0.CO
[13]  
2-W
[14]   RETRACTED: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (Retracted article. See vol. 9, p. 1221, 2003) [J].
Kugler, A ;
Stuhler, G ;
Walden, P ;
Zöller, G ;
Zobywalski, A ;
Brossart, P ;
Trefzer, U ;
Ullrich, S ;
Müller, CA ;
Becker, V ;
Gross, AJ ;
Hemmerlein, B ;
Kanz, L ;
Müller, GA ;
Ringert, RH .
NATURE MEDICINE, 2000, 6 (03) :332-336
[15]   Medical progress -: Acute myeloid leukemia [J].
Löwenberg, B ;
Downing, JR ;
Burnett, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (14) :1051-1062
[16]  
Lowenberg B, 1997, J CLIN ONCOL, V15, P3496
[17]   Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells [J].
Mackensen, A ;
Dräger, R ;
Schlesier, M ;
Mertelsmann, R ;
Lindemann, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (03) :152-156
[18]   Dendritic cells: Specialized and regulated antigen processing machines [J].
Mellman, I ;
Steinman, RM .
CELL, 2001, 106 (03) :255-258
[19]   Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [J].
Nestle, FO ;
Alijagic, S ;
Gilliet, M ;
Sun, YS ;
Grabbe, S ;
Dummer, R ;
Burg, G ;
Schadendorf, D .
NATURE MEDICINE, 1998, 4 (03) :328-332
[20]  
OSSENKOPPELE GJ, 2003, IN PRESS LEUKEMIA